Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study

Ketty Peris, Paolo Bossi, Piergiacomo Calzavara-Pinton, Paola Queirolo, Salvatore Alfieri, Marco Palla, Maria Teresa Rossi, Francesco Spagnolo, Cinzia Astolfi, Paolo A Ascierto

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Aim: To assess safety and efficacy of vismodegib in the Italian cohort from the SafeTy Events in VIsmodEgib study. Materials & methods: Data from Italian patients with locally advanced basal cell carcinoma (laBCC) or metastatic BCC were analyzed. Results: Among 182 Italian patients, adverse events occurred with similar incidence to the overall population. Overall response rate was 67.1% in laBCC, 20% in metastatic BCC; complete response rate was 33.1% overall and 37.4% in laBCC. Median time to response was 2 months in complete responders versus 3.6 months overall. Quality of life improved from baseline. Conclusion: In the Italian cohort of STEVIE, vismodegib showed a safety profile consistent with the whole population; older age did not affect safety or efficacy. ClinicalTrials.gov registration: NCT0136766.
Lingua originaleEnglish
pagine (da-a)1091-1100
Numero di pagine10
RivistaFuture Oncology
Volume16
DOI
Stato di pubblicazionePubblicato - 2020

Keywords

  • Gorlin syndrome
  • HhAntag691
  • basal cell
  • carcinoma
  • vismodegib

Fingerprint Entra nei temi di ricerca di 'Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study'. Insieme formano una fingerprint unica.

Cita questo